HRT Financial’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$264K Buy
+107,524
New +$360K ﹤0.01% 2982
2025
Q3
Sell
-25,110
Closed -$60K 3232
2025
Q2
$60K Buy
25,110
+9,119
+57% +$12.4K ﹤0.01% 2287
2025
Q1
$13K Buy
15,991
+2,904
+22% +$2.76K ﹤0.01% 2333
2024
Q4
$11K Buy
+13,087
New +$14.6K ﹤0.01% 2267
2024
Q1
Sell
-17,354
Closed -$32K 2651
2023
Q4
$32K Buy
+17,354
New +$25.9K ﹤0.01% 1997
2023
Q1
Sell
-37,741
Closed -$157K 2799
2022
Q4
$157K Buy
+37,741
New +$143K ﹤0.01% 1988
2022
Q3
Sell
-46,159
Closed -$521K 3132
2022
Q2
$521K Buy
+46,159
New +$553K 0.01% 1442

Other funds holding NBP

HRT Financial's NBP Position: Q1 2026 in Review

HRT Financial opened a new position in NovaBridge Biosciences American Depositary Shares (NBP) in Q1 2026: 107,524 shares worth $264K. The stake represents ﹤0.01% of the portfolio and ranks #2982 among its holdings. This is a return to the name: HRT Financial previously reported a position in NBP as recently as Q2 2025.

HRT Financial first reported a position in NBP in Q2 2022 and has held it in 7 quarters since. The position peaked at $521K in Q2 2022. 48 funds tracked by Wall St. Rank hold NBP as of Q1 2026.

  • HRT Financial held 107,524 shares of NovaBridge Biosciences American Depositary Shares worth $264K as of Q1 2026.
  • NovaBridge Biosciences American Depositary Shares was a new HRT Financial position in Q1 2026.
  • NovaBridge Biosciences American Depositary Shares made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2982 holding.
  • HRT Financial first reported a position in NovaBridge Biosciences American Depositary Shares in Q2 2022 and has held it in 7 quarters since.
  • HRT Financial's NovaBridge Biosciences American Depositary Shares position peaked at $521K in Q2 2022.
  • 48 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.